AHA Coding Clinic® for ICD-9 - 1989 Second Quarter
Myelodysplastic syndrome, 238.7
The International Agency for Research in Cancer (IARC) has recently identified myelodysplastic syndrome as a neoplastic condition. The National Cancer Institute has also concurred with this finding. Based upon this new information, myelodysplastic syndrome is now classified as neoplastic. Therefore, the correct code assignment is 238.7, Neoplasm of uncertain behavior of other lymphatic and hematopoietic tissues. Prior to the IARC's finding, myelodysplastic syndrome was classified to 289.8, Other specified diseases of blood and blood-forming organs, as published in the March-April 1987 Coding Clinic. Note:As of October 1, 2006, code 238.7 has been expanded to the fifth...
Subscribe or sign in to view the full article.
Article Overview
This article discusses a coding update tied to the classification of myelodysplastic syndrome and references historical ICD-9-CM code placement. It is relevant to coders, compliance staff, and healthcare teams working with blood and blood-forming organ diagnoses and code-change history.
Why This Topic Matters
Correct diagnosis coding depends on current classification guidance and on understanding how legacy codes were revised over time. This article helps readers recognize the broader ICD-9-CM context for myelodysplastic syndrome and related hematologic conditions.
What You Will Learn
- How the article frames myelodysplastic syndrome within a neoplastic classification context
- How historical ICD-9-CM code placement for the condition is discussed
- What code expansion notes are referenced for later effective dates
- How the article relates classification findings to coding updates
Who Should Read This
- Medical coders
- Coding auditors
- Compliance professionals
- Billing staff
- Clinical documentation teams
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com